GlaxoSmithKline (GS71) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GS71 Analyst Ratings

Hold

2 Buy

10 Hold

3 Sell

Based on 15 analysts giving stock ratings to

GlaxoSmithKline

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GS71 Stock 12 Month Forecast

Average Price Target

CHF23.49

▼(-10.06% Downside)

Based on 15 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is CHF23.49 with a high forecast of CHF33.38 and a low forecast of CHF18.85. The average price target represents a -10.06% change from the last price of CHF26.12.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"CHF17","34":"CHF34","21.25":"CHF21.3","25.5":"CHF25.5","29.75":"CHF29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.376356706,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF33.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.4925176055,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF23.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.85043402,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF18.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.25,25.5,29.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,26.673565900461536,27.232131800923074,27.790697701384616,28.349263601846154,28.907829502307692,29.46639540276923,30.024961303230768,30.58352720369231,31.142093104153847,31.700659004615385,32.25922490507693,32.817790805538465,{"y":33.376356706,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,25.91327058503846,25.711541170076924,25.509811755115383,25.308082340153845,25.106352925192308,24.90462351023077,24.70289409526923,24.501164680307692,24.299435265346155,24.097705850384617,23.895976435423076,23.69424702046154,{"y":23.4925176055,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.115,25.556187232307693,24.997374464615383,24.438561696923077,23.879748929230768,23.320936161538462,22.762123393846153,22.203310626153847,21.644497858461538,21.085685090769232,20.526872323076923,19.968059555384617,19.40924678769231,{"y":18.85043402,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.115,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 21</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.115,"date":1790812800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF33.38

Average Price TargetCHF23.49

Lowest Price TargetCHF18.85

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Zain Ebrahim

J.P. Morgan

CHF18.85

Sell

-27.83%

Downside

Reiterated

10/01/26

GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan

Emmanuel Papadakis

Deutsche Bank

CHF22.18

Hold

-15.10%

Downside

Reiterated

09/29/26

Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

James Gordon CFA

Barclays

CHF19.96

Sell

-23.59%

Downside

Reiterated

09/29/26

Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

Michael Leuchten

Jefferies

CHF27.72

Buy

6.13%

Upside

Reiterated

09/29/26

Jefferies Remains a Buy on GlaxoSmithKline (GSK)

Trung Huynh

RBC Capital

CHF21.9

Hold

-16.17%

Downside

Reiterated

09/21/26

RBC Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Matthew Weston

UBS

―

Hold

―

Reiterated

09/17/26

UBS Remains a Hold on GlaxoSmithKline (GSK)

Kerry Holford

Berenberg Bank

CHF22.17→CHF24.39

Hold

-6.62%

Downside

Reiterated

09/15/26

Berenberg Bank Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Graham Parry

Citi

CHF23.29

Hold

-10.85%

Downside

Reiterated

09/15/26

GlaxoSmithKline (GSK) Receives a Hold from Citi

Rajesh Kumar

HSBC

CHF20.62→CHF22.17

Hold

-15.10%

Downside

Reiterated

09/10/26

GSK price target raised to 2,000 GBp from 1,860 GBp at HSBCGSK price target raised to 2,000 GBp from 1,860 GBp at HSBC

Sachin Jain

Bank of America Securities

CHF26.06

Hold

-0.25%

Downside

Reiterated

09/04/26

GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp

Sarita Kapila

Morgan Stanley

CHF19.4→CHF21.07

Sell

-19.35%

Downside

Reiterated

08/25/26

Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)

Justin Smith

Bernstein

CHF31.32→CHF33.38

Buy

27.78%

Upside

Reiterated

08/03/26

Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)

Rajan Sharma

Goldman Sachs

CHF20.73→CHF20.95

Hold

-19.77%

Downside

Reiterated

07/28/26

GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

07/09/26

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Zain Ebrahim

J.P. Morgan

CHF18.85

Sell

-27.83%

Downside

Reiterated

10/01/26

GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan

Emmanuel Papadakis

Deutsche Bank

CHF22.18

Hold

-15.10%

Downside

Reiterated

09/29/26

Deutsche Bank Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)

James Gordon CFA

Barclays

CHF19.96

Sell

-23.59%

Downside

Reiterated

09/29/26

Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

Michael Leuchten

Jefferies

CHF27.72

Buy

6.13%

Upside

Reiterated

09/29/26

Jefferies Remains a Buy on GlaxoSmithKline (GSK)

Trung Huynh

RBC Capital

CHF21.9

Hold

-16.17%

Downside

Reiterated

09/21/26

RBC Capital Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Matthew Weston

UBS

―

Hold

―

Reiterated

09/17/26

UBS Remains a Hold on GlaxoSmithKline (GSK)

Kerry Holford

Berenberg Bank

CHF22.17→CHF24.39

Hold

-6.62%

Downside

Reiterated

09/15/26

Berenberg Bank Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Graham Parry

Citi

CHF23.29

Hold

-10.85%

Downside

Reiterated

09/15/26

GlaxoSmithKline (GSK) Receives a Hold from Citi

Rajesh Kumar

HSBC

CHF20.62→CHF22.17

Hold

-15.10%

Downside

Reiterated

09/10/26

GSK price target raised to 2,000 GBp from 1,860 GBp at HSBCGSK price target raised to 2,000 GBp from 1,860 GBp at HSBC

Sachin Jain

Bank of America Securities

CHF26.06

Hold

-0.25%

Downside

Reiterated

09/04/26

GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp

Sarita Kapila

Morgan Stanley

CHF19.4→CHF21.07

Sell

-19.35%

Downside

Reiterated

08/25/26

Morgan Stanley Keeps Their Sell Rating on GlaxoSmithKline (GSK)

Justin Smith

Bernstein

CHF31.32→CHF33.38

Buy

27.78%

Upside

Reiterated

08/03/26

Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

07/29/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (NASDAQ: CRSP) and GlaxoSmithKline (LSE: GB:GSK)

Rajan Sharma

Goldman Sachs

CHF20.73→CHF20.95

Hold

-19.77%

Downside

Reiterated

07/28/26

GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

07/09/26

Guggenheim Remains a Hold on GlaxoSmithKline (GSK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

OMCLOmnicell

KNSAKiniksa Pharmaceuticals

ACHVAchieve Life Sciences

AHCOAdaptHealth

ZVRAZevra Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months

James Gordon CFABarclays

Success Rate

8/9 ratings generated profit

Average Return

+3.18%

Copying James Gordon CFA's trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +3.18% per trade.

1 Year

James Gordon CFABarclays

Success Rate

8/9 ratings generated profit

Average Return

+5.03%

Copying James Gordon CFA's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +5.03% per trade.

2 Years

James Gordon CFABarclays

Success Rate

8/9 ratings generated profit

Average Return

+5.03%

Copying James Gordon CFA's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +5.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GS71 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GS71 has received 4 Buy Ratings, 15 Hold Ratings, and 13 Sell Ratings. GS71 average Analyst price target in the past 3 months is 23.49.

Each month's total comprises the sum of three months' worth of ratings.

GS71 Financial Forecast

GS71 Earnings Forecast

Next quarter’s earnings estimate for GS71 is CHF0.57 with a range of CHF0.52 to CHF0.61. The previous quarter’s EPS was CHF0.56. GS71 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Sales Forecast

Next quarter’s sales forecast for GS71 is CHF9.86B with a range of CHF9.69B to CHF9.96B. The previous quarter’s sales results were CHF9.32B. GS71 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GS71 has Performed in-line its overall industry.

GS71 Stock Forecast FAQ

What is CH:GS71’s average 12-month price target, according to analysts?

Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 23.49.

What is CH:GS71’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:GS71, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GlaxoSmithKline a Buy, Sell or Hold?

GlaxoSmithKline has a consensus rating of Hold, which is based on 2 buy ratings, 10 hold ratings and 3 sell ratings.

What is GlaxoSmithKline’s share price target?

The average share price target for GlaxoSmithKline is 23.49. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF33.38 ,and the lowest forecast is CHF18.85. The average share price target represents -10.06% Decrease from the current price of CHF26.12.

What do analysts say about GlaxoSmithKline?

GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of GlaxoSmithKline?

To buy shares of CH:GS71, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

GlaxoSmithKline (GS71) Stock Forecast & Price Target

GS71 Analyst Ratings

GS71 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering GlaxoSmithKline

GS71 Analyst Recommendation Trends

GS71 Financial Forecast

GS71 Earnings Forecast

GS71 Sales Forecast

GS71 Stock Forecast FAQ

Detailed List of Analyst Forecasts